• Alias: AMG 479
    • A recombinant fully human mAb that binds to membrane-bound IGF-1R, subsequently triggering PI3K/AKT signaling pathway
    • Phase 2 in metastatic Ewing sarcoma, in mutant KRAS mCRC in combination with FOLFIRI or metastatic pancreatic cancer.
    • Phase 1 dose: Up to 20 mg/kg IV every 2 weeks; proposed dose 6 to 12 mg/kg IV Q 2 weeks in combination with cytotoxic chemotherapy or targeted therapy
    • Half-life: Ranges between 7 and 11 days
    • Common side effects: Hyperglycemia, fatigue, nausea/vomiting, anorexia, neutropenia, thrombocytopenia, increased AST
    (Tolcher et al., 2009)
    Other topics in Targeted and Immunotherapy Agents